Viability Assay vs. SW480

Generation of Novel Monoclonal Antibodies
Binding to Cancer Targets Using Diverse
Display Libraries
Michael Spruyt, Frank Buquicchio, Leigh-Ann Ricks &
Neil Goldstein
Helio Genetics Inc
46 DeForrest Avenue
East Hanover NJ 07936
Contact: Neil Goldstein, Ph.D.
[email protected]
973 342-7996
HelioGenetics Inc
ABSTRACT
HelioGenetics has developed a rapid approach for generating and
characterizing monoclonal IgG heavy chain molecules as an alternative
to
the
widely
used
methods
for
identifying
monoclonal
antibodies.
These molecules are derived from highly diverse DNA
libraries consisting of randomized binding sites and include antigen
binding sequences outside of the normal human repertoire. In-vitro
selection identifies highly specific target binders and subsequent in-vitro
functional
screening
allows
for
the
selection
of
bio-active
molecules. Overall, our technology can yield humanized antibodies
which
cannot
be
produced
via
traditional
poly/monoclonal
methodologies. Using this approach, we have developed antibodies to a
number of cancer related targets including Axl, MerRT, ErbB3, EGFR, PDL1 and c-Met.
One of our Axl “antibodies” has been further
characterized and shown to bind to the appropriate Axl-expressing tumor
cells lines and inhibit their growth in vitro. Additional studies are
underway to further delineate the utility of this and other antibodies as
candidates for further clinical development.
HelioGenetics Inc
INTRODUCTION
The RAE system overcomes limitations of current methods for the isolation
of human antibodies which bind to antigens of choice with high affinities
and specificities. Human antibodies are required for many therapeutic
applications. However, current methods for obtaining human antibodies
with required bioactivities for therapeutic use are often unreliable. These
methods include isolating antigen-specific hybridomas from human
antibody-producing transgenic mice, and isolating antigen-specific human
antibody genes from libraries displayed on bacteriophage, cells, or
ribosomes by biopanning.
The RAE system takes advantage of complete randomization of
the
antibody binding sites on the heavy and light chain of a human antibody to
identify target specific binders with biological activity. The system allows
“biology” (i.e., biopanning of recombinant targets or tissue culture cells) to
make a decision about which CDR sequence(s) is important for binding. A
high level of diversity is obtained from both the random nature of the amino
acid sequences of the antigen binding sites plus the potential for “repetitive
length” within the sites themselves.
HelioGenetics Inc
BENEFITS OF THE RAE SYSTEM
•
RAE = Randomized Antibody Engineering
•
Ability to identify and perform initial biological characterization of
target-specific binders within 5 weeks
•
Total randomization of antigen binding sites allowing “biology” to
optimize target-specific sequence(s)
•
Additional diversity derives from “ repetitive length” within antibody
binding site
•
Targets include recombinant proteins and proteins expressed in situ on
tissue culture cells
HelioGenetics Inc
ANTIBODY CONSTRUCT IN M13 PHAGE
NH2-
FLAG
Antibody
ETag
gene III protein
cloning site
gene III
Phagemid
Phage Display on pIII:
3+3 Phagemid System
M13 ori
pUC ori
HelioGenetics Inc
-COOH
BIOPANNING PROTOCOL
Antibody
Libraries
Wash
Bind to Target
Repeat
3-4
cycles
H+ etc.
Target specific
Antibodys
Elute
Amplify
A target is first coated on an immobilized surface (e.g., microtiter plates). A phage library is added for several hr and non-binders
removed by extensive washing. Target-specific phage are eluted with a low pH buffer and amplified overnight at 37oC in combination
with helper phage. Usually 3-5 rounds are needed to identify target-specific binders and eliminate non-specific phage.
HelioGenetics Inc
TIME LINE TO ID TARGET-SPECIFIC
ANTIBODIES
Day
Day
Day
Day
Day
Day
Day
0:
1-4:
5-6:
6-7:
7-8:
9:
10-13:
Day 14-18:
Day 19:
Day 20-23:
Day
Day
Day
Day
24-28:
28-31:
32-35:
36:
HelioGenetics Inc
Coat target or cells on solid support
Pan with high diversity antibody display library
Plate and identify antibody expressing colonies
Prepare “Master Plate”
Rescue antibody expressing colonies
ELISA vs. target or cells to identify binders
PCR to identify clones; insert into expression
vector; mini-preps for antibody expression studies
Transient transfection in 293 cells
ELISA for antibody expression
Maxi-preps of clones positive for antibody
expression
Transient expression in 293 cells
ELISA for antibody expression
Biological assay(s) to determine antibody activity
Go/No Go for stable expression and further
biological and biochemical characterization
SIZE DISTRIBUTION IN A RAE LIBRARY
HelioGenetics Inc
ATTRIBUTES OF AN ANTI-AXL ANTIBODY
•
Derived using RAE Technology vs. recombinant Axl
•
Binds to purified Axl and Axl-expressing cancer cells
•
Novel amino acid sequence in CDR3
•
Can be produced in 293 and CHO cells
•
2-step selection process has been used to select for binding
only in absence of GAS6
•
Inhibits growth of cancer cells independent of added Gas6
HelioGenetics Inc
AXL ANTIBODY: EFFECTS ON HUMAN
CANCER CELLS
A549
Axl Antibody
Control Ig
H1299
Axl Antibody
Control Ig
SW480
Axl Antibody
Control Ig
10
9
8
7
6
5
4
3
2
1
+ Gas6
0
A549
Axl Antibody
10
Control Ig
9
5
10
15
20
8
7
H1299
Axl Antibody
6
Control Ig
5
No Gas6
4
3
SW480
Axl Antibody
2
Control Ig
1
0
5
10
15
20
SW480 (colorectal carcinoma), H1299 (non-small cell lung cancer) and A549 (lung cancer) are plated in 96 well microtiter plates at 5000 cells per
well in 100ul DMEM containing 1% FBS and incubated overnight at 37C. Axl antibody and controls are added to the appropriate wells in the presence
or absense of Gas6 (200ng/ml) and incubated for 72 at 37C. Viability is determined using WST-8 (Sigma) and read at 450nM at various times.
HelioGenetics Inc
TARGETED CELLS EXPRESS AXL & GAS6
1
2 3 4
5 6
RT-PCR: SW480
Lane 1 Marker
Lane 2 Actin Control
Lane 3 Axl
Lane 4 Gas
Lane 5 EGFR
Lane 6 IGFR
Western Blot
Phosphorylation ELISA
From Li et al., Oncogene 28 3442 (2009)
HelioGenetics Inc
VIABILITY ASSAY VS. SW480
Medium Control
Control Antibody
Axl Antibody
Cl 163
Cl 36
Cl 8
Cl 243
Cl 247
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
OD 450
SW480 cells (colorectal cancer) are plated in 96 well microtiter plates at 5000 cells per well in 100ul DMEM containing 1% FBS and incubated overnight
at 37C. Samples and appropriate controls (100ul/well) are added and the plates incubated for 72 hours. 10ul of WST-8 (Sigma) are added to each well
and the plates read at 1, 2, 3 and 4 hours in an ELISA reader at 450nM. Antibodies: Control antibody, anti-IL-8; anti-Axl antibody (vs. recombinant Axl); cl
163, anti-MerRT; cl 36, anti-Axl; cl 8, anti-ErbB3; cl 243 and 247, anti-Axl-Gas6 complex with negative pan.
HelioGenetics Inc
BIOLOGICAL EFFECTS OF ANTIBODIES ON
SW480
Phase
Phase
Stained
Medium
Control
Cl 243
Control
Antibody
Cl 163
Axl
Cl 247
Stained
Cl 36
Cl 8
Antibodies: Control antibody, anti-IL-8; anti-Axl antibody (vs. recombinant Axl); cl 163, anti-MerRT; cl 36, antiAxl; cl 8, anti-ErbB3; cl 243 and 247, anti-Axl-Gas6 complex with negative pan.
HelioGenetics Inc
SIZE DISTRIBUTION OF ANTI-AXL & ANTIMER ANTIBODIES
Anti-Axl
HelioGenetics Inc
Anti-Mer RT
TARGETS PANNED
Recombinant
Targets
•
Axl receptor
•
Mer receptor
•
PD-L1
•
EGFR
•
ErbB3
•
PDGFR
•
FGFR
HelioGenetics Inc
Cancer Cells
• Pancreatic
• Breast
• Melanoma
• NSCLC
• Ovarian
OVERVIEW
• Rapid generation
antibodies
and
characterization
• Targets can be purified recombinant
expressed in situ on tissue culture cells
of
target-specific
proteins
or
those
• Secondary libraries can be generated to improve affinity,
potency and selectivity
• Antibodies are biologically active
• Novel composition of matter for IP protection
• Available for research collaborations and partnerships
HelioGenetics Inc